TNF-α-blokkoló kezelés krónikus, ismeretlen eredetu gyulladásos bélbetegségekben

Translated title of the contribution: TNF-α blocking therapy in chronic inflammatory bowel disease

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The introduction of TNF-α blocking therapy has produced a dramatic change in the treatment of therapy resistant patients with inflammatory bowel disease. Both infliximab and adalimumab are effective in middle severe and severe Crohn's disease. Besides, infliximab is potent in the remission and its sustaining in ulcerative colitis. However, among therapy resistant individuals, 20-30 percents of patients with Crohn's disease and 30-40 percents of patients with ulcerative colitis do not respond to these treatments. To date, no comparative study between the two drugs has been carried out and the clinical trials can not be directly compared to each others, still, on the basis of general considerations, there is no essential difference in the effectiveness between the two treatments.

Original languageHungarian
Pages (from-to)1773-1779
Number of pages7
JournalOrvosi Hetilap
Volume150
Issue number38
DOIs
Publication statusPublished - Sep 1 2009

Fingerprint

Inflammatory Bowel Diseases
Ulcerative Colitis
Crohn Disease
Therapeutics
Clinical Trials
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

TNF-α-blokkoló kezelés krónikus, ismeretlen eredetu gyulladásos bélbetegségekben. / Molnár, T.

In: Orvosi Hetilap, Vol. 150, No. 38, 01.09.2009, p. 1773-1779.

Research output: Contribution to journalArticle

@article{c91243801404438194a135ce90cb66ac,
title = "TNF-α-blokkol{\'o} kezel{\'e}s kr{\'o}nikus, ismeretlen eredetu gyullad{\'a}sos b{\'e}lbetegs{\'e}gekben",
abstract = "The introduction of TNF-α blocking therapy has produced a dramatic change in the treatment of therapy resistant patients with inflammatory bowel disease. Both infliximab and adalimumab are effective in middle severe and severe Crohn's disease. Besides, infliximab is potent in the remission and its sustaining in ulcerative colitis. However, among therapy resistant individuals, 20-30 percents of patients with Crohn's disease and 30-40 percents of patients with ulcerative colitis do not respond to these treatments. To date, no comparative study between the two drugs has been carried out and the clinical trials can not be directly compared to each others, still, on the basis of general considerations, there is no essential difference in the effectiveness between the two treatments.",
keywords = "Adalimumab, Crohn's disease, IBD, Infliximab, TNF-α, Ulcerative colitis",
author = "T. Moln{\'a}r",
year = "2009",
month = "9",
day = "1",
doi = "10.1556/OH.2009.28689",
language = "Hungarian",
volume = "150",
pages = "1773--1779",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "38",

}

TY - JOUR

T1 - TNF-α-blokkoló kezelés krónikus, ismeretlen eredetu gyulladásos bélbetegségekben

AU - Molnár, T.

PY - 2009/9/1

Y1 - 2009/9/1

N2 - The introduction of TNF-α blocking therapy has produced a dramatic change in the treatment of therapy resistant patients with inflammatory bowel disease. Both infliximab and adalimumab are effective in middle severe and severe Crohn's disease. Besides, infliximab is potent in the remission and its sustaining in ulcerative colitis. However, among therapy resistant individuals, 20-30 percents of patients with Crohn's disease and 30-40 percents of patients with ulcerative colitis do not respond to these treatments. To date, no comparative study between the two drugs has been carried out and the clinical trials can not be directly compared to each others, still, on the basis of general considerations, there is no essential difference in the effectiveness between the two treatments.

AB - The introduction of TNF-α blocking therapy has produced a dramatic change in the treatment of therapy resistant patients with inflammatory bowel disease. Both infliximab and adalimumab are effective in middle severe and severe Crohn's disease. Besides, infliximab is potent in the remission and its sustaining in ulcerative colitis. However, among therapy resistant individuals, 20-30 percents of patients with Crohn's disease and 30-40 percents of patients with ulcerative colitis do not respond to these treatments. To date, no comparative study between the two drugs has been carried out and the clinical trials can not be directly compared to each others, still, on the basis of general considerations, there is no essential difference in the effectiveness between the two treatments.

KW - Adalimumab

KW - Crohn's disease

KW - IBD

KW - Infliximab

KW - TNF-α

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=70349215021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349215021&partnerID=8YFLogxK

U2 - 10.1556/OH.2009.28689

DO - 10.1556/OH.2009.28689

M3 - Article

VL - 150

SP - 1773

EP - 1779

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 38

ER -